JP2008520707A5 - - Google Patents

Download PDF

Info

Publication number
JP2008520707A5
JP2008520707A5 JP2007543288A JP2007543288A JP2008520707A5 JP 2008520707 A5 JP2008520707 A5 JP 2008520707A5 JP 2007543288 A JP2007543288 A JP 2007543288A JP 2007543288 A JP2007543288 A JP 2007543288A JP 2008520707 A5 JP2008520707 A5 JP 2008520707A5
Authority
JP
Japan
Prior art keywords
dose
predetermined
surgically created
size
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/041884 external-priority patent/WO2006073586A2/en
Publication of JP2008520707A publication Critical patent/JP2008520707A/ja
Publication of JP2008520707A5 publication Critical patent/JP2008520707A5/ja
Pending legal-status Critical Current

Links

JP2007543288A 2004-11-17 2005-11-17 放射線量測定法及び遮断抗体並びに癌を治療する際の該方法及び使用 Pending JP2008520707A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62874004P 2004-11-17 2004-11-17
PCT/US2005/041884 WO2006073586A2 (en) 2004-11-17 2005-11-17 Radiation dosimetry and blocking antibodies and methods and uses threfor in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2008520707A JP2008520707A (ja) 2008-06-19
JP2008520707A5 true JP2008520707A5 (enExample) 2008-12-18

Family

ID=36647943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543288A Pending JP2008520707A (ja) 2004-11-17 2005-11-17 放射線量測定法及び遮断抗体並びに癌を治療する際の該方法及び使用

Country Status (8)

Country Link
US (1) US20060127311A1 (enExample)
EP (1) EP1817062A4 (enExample)
JP (1) JP2008520707A (enExample)
AU (1) AU2005323377A1 (enExample)
CA (1) CA2587172A1 (enExample)
RU (1) RU2007121808A (enExample)
WO (1) WO2006073586A2 (enExample)
ZA (1) ZA200704642B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681790A1 (en) * 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
CN114404429B (zh) * 2021-11-30 2023-06-30 重庆医科大学附属第二医院 一种纳米银修饰的单宁酸-铁网络的载药纳米复合物及其制备方法和逆转肿瘤耐药应用
CN120813388A (zh) * 2023-03-02 2025-10-17 日本医事物理股份有限公司 放射性金属标记抗体、放射性药物及化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
USRE38008E1 (en) * 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US6787153B1 (en) * 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
AU6445894A (en) * 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US6022521A (en) * 1995-05-04 2000-02-08 The Regents Of The University Of Michigan Method of establishing the optimal radiation dose for radiopharmaceutical treatment of disease
AU3544599A (en) * 1998-01-16 1999-08-02 Paul E. Borchardt Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease
JP5099944B2 (ja) * 1998-06-04 2012-12-19 スミスクライン ビーチャム コーポレーション 患者特異的薬量測定
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US20020187100A1 (en) * 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
US6455026B1 (en) * 2001-03-23 2002-09-24 Agy Therapeutics, Inc. Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
US7011814B2 (en) * 2001-04-23 2006-03-14 Sicel Technologies, Inc. Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject

Similar Documents

Publication Publication Date Title
Hasegawa et al. Dual-modality imaging of function and physiology
Liu et al. Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers
Avril et al. Monitoring response to treatment in patients utilizing PET
Knox et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer
ES2802234T3 (es) Sistemas y métodos para determinar la dosis óptima y específica para el paciente de anticuerpos dirigidos al tumor
RU2019142507A (ru) Композиции, способы и системы для синтеза и применение визуализирующих средств
CN103890611A (zh) 数据驱动的对事件接受/拒绝逻辑的优化
Pfeifer et al. Effect of Ritonavir on 99mTechnetium–Mebrofenin Disposition in Humans: A Semi‐PBPK Modeling and In Vitro Approach to Predict Transporter‐Mediated DDIs
JPH07501000A (ja) 歩行可能なクリアランス機能モニター
Wong et al. Characterization of [11C] RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans
Nakahara et al. Rat model of cardiotoxic drug-induced cardiomyopathy
Zacherl et al. Molecular imaging of cardiac CXCR4 expression in a mouse model of acute myocardial infarction using a novel 68Ga-mCXCL12 PET tracer
Deloar et al. Internal absorbed dose estimation by a TLD method for-FDG and comparison with the dose estimates from whole body PET
JPH11505450A (ja) 疾病の放射性医薬品治療のための最適線量の設定法
JP2008520707A5 (enExample)
Forrer et al. From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo 99mTc-DMSA-SPECT and molecular imaging
JP5457191B2 (ja) 被検体内の放射性医薬品の分布を決定するシステム、方法及びコンピュータプログラム
Fayssoil et al. Analyzing left ventricular function in mice with Doppler echocardiography
Cherry et al. Quantitative in vivo measurements of tumor perfusion using rubidium-81 and positron emission tomography
Aktolun et al. Nuclear oncology
CN102665536B (zh) 借助于定量测量底物的代谢来确定生物的肝脏性能的方法
Saleem et al. Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes
Mahmoudi et al. Patient-specific dosimetry in radioligand therapy (RLT) for metastatic prostate cancer using 177Lu-DKFZ-PSMA-617
Liu et al. Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody
US20120288442A1 (en) Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis